TOKYO – Rani Therapeutics LLC is working on a delivery system for insulin that could provide relief for millions of people who must undergo regular painful injections to deal with conditions such as diabetes, rheumatoid arthritis, osteoporosis and multiple sclerosis.
HONG KONG — Defects in fatty acid-binding proteins (FABPs) may help to explain the pathology in some cases of schizophrenia and autism spectrum disorders (ASDs), possibly leading to the development of tailor-made therapies for those mental disorders, Japanese neuroscientists reported.
SHANGHAI – HD Biosciences Co. Ltd. has signed an agreement to co-develop drugs with two research centers at Marshall University. The deal was struck after three years of informal collaboration between both sides, and with an eye to entering the clinic in the next two years. The focus of the alliance is to provide innovative medicines for unmet medical needs, particularly cancer and kidney fibrosis, in both China and the U.S.
HONG KONG – Sinopharm Group, one of the largest biotech companies in China, is likely to undergo major structural reforms as the government kicks off a series of reforms on its state-owned enterprises (SOEs).
SHANGHAI – Pharmamar SA, of Madrid, has licensed the commercial rights to Aplidin (plitidepsin), an antitumour agent for multiple myeloma used in conjunction with dexamethasone, to Chugai Pharmaceutical Marketing Ltd., the European arm of Japanese parent company Chugai Pharmaceutical.
SHANGHAI – Cellular Biomedicine Group Inc. (CBMG), of Shanghai, has had a busy month, successfully listing on Nasdaq as the first "pureplay" biotech company from China and closing a $10 million stock transaction.
Beike Biotechnology Co. Ltd., of Shenzhen, China, said following the recent Chinese Food and Drug Administration acceptance of its investigational new drug application seeking use of human umbilical cord-derived mesenchymal stem cells to treat lupus, the company anticipates approval to move ahead with the treatment by the end of this year.
Strand Life Sciences, of Bangalore, India, appointed Scott Storrer president of North America. He will oversee strategy, expansion and operation of Strand Genomics Inc..
RSS